PT  - JOURNAL ARTICLE
AU  - Reijns, Martin A.M.
AU  - Thompson, Louise
AU  - Acosta, Juan Carlos
AU  - Black, Holly A.
AU  - Sanchez-Luque, Francisco J.
AU  - Diamond, Austin
AU  - Parry, David A.
AU  - Daniels, Alison
AU  - O’Shea, Marie
AU  - Uggenti, Carolina
AU  - Sanchez, Maria C.
AU  - O’Callaghan, Alan
AU  - McNab, Michelle L.L.
AU  - Adamowicz, Martyna
AU  - Friman, Elias T.
AU  - Hurd, Toby
AU  - Jarman, Edward J.
AU  - Mow Chee, Frederic Li
AU  - Rainger, Jacqueline K.
AU  - Walker, Marion
AU  - Drake, Camilla
AU  - Longman, Dasa
AU  - Mordstein, Christine
AU  - Warlow, Sophie J.
AU  - McKay, Stewart
AU  - Slater, Louise
AU  - Ansari, Morad
AU  - Tomlinson, Ian P.M.
AU  - Moore, David
AU  - Wilkinson, Nadine
AU  - Shepherd, Jill
AU  - Templeton, Kate
AU  - Johannessen, Ingolfur
AU  - Tait-Burkard, Christine
AU  - Haas, Jürgen G.
AU  - Gilbert, Nick
AU  - Adams, Ian R.
AU  - Jackson, Andrew P.
TI  - A sensitive and affordable multiplex RT-qPCR assay for SARS-CoV-2 detection
AID  - 10.1101/2020.07.14.20154005
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.14.20154005
4099  - http://medrxiv.org/content/early/2020/10/30/2020.07.14.20154005.short
4100  - http://medrxiv.org/content/early/2020/10/30/2020.07.14.20154005.full
AB  - With the ongoing COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, there is need for sensitive, specific and affordable diagnostic tests to identify infected individuals, not all of whom are symptomatic. The most sensitive test involves the detection of viral RNA using RT-qPCR, with many commercial kits now available for this purpose. However, these are expensive and supply of such kits in sufficient numbers cannot always be guaranteed. We therefore developed a multiplex assay using well-established SARS-CoV-2 targets alongside a human cellular control (RPP30) and a viral spike-in control (PhHV-1), which monitor sample quality and nucleic acid extraction efficiency respectively. Here, we establish that this test performs as well as widely used commercial assays, but at substantially reduced cost. Furthermore, we demonstrate >1,000-fold variability in material routinely collected by nose-and-throat swabbing, and establish a statistically significant correlation between the detected level of human and SARS-CoV-2 nucleic acids. The inclusion of the human control probe in our assay therefore provides a quantitative measure of sample quality that could help reduce false negative rates. We demonstrate feasibility of establishing a robust RT-qPCR assay at ∼10% of the cost of equivalent commercial assays, which could benefit low resource environments and make high volume testing more affordable.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCT-B and MOS were funded by BBSRC Institute Strategic Programme grant funding (BBS/E/D/20002172, BBS/E/D/20002173). This work was supported by a UK Medical Research Council Human Genetics Unit core grant (MRC, U127580972) and by NHS National Services Scotland, as part of a technology development exercise at the NHS-led University of Edinburgh/NHS Lothian COVID-19 testing centre at the Institute of Genetics and Molecular Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Tissue Governance for the South East Scotland Scottish Academic Health Sciences Collaboration Human Annotated BioResourceAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesn/a